FFRangio System vs Acumen Hypotension Prediction Index (HPI) Feature Software

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FFRangio System

by CathWorks (acquired by Medtronic)

Acumen Hypotension Prediction Index (HPI) Feature Software

by Edwards Lifesciences

AI Verdict

These two healthcare AI tools are adjacent in their application within cardiology, but address distinct clinical problems. The FFRangio System is designed for optimizing PCI decisions in coronary artery disease by providing wire-free FFR guidance, while the Acumen Hypotension Prediction Index (HPI) software focuses on predicting and managing hypotensive events to improve hemodynamic stability. A healthcare provider would likely consider these for different departments or specific patient care scenarios.

Choose FFRangio System if…

Choose the FFRangio System if your cardiology department requires a non-invasive, wire-free solution for comprehensive coronary physiology assessment and PCI guidance. This tool is ideal for interventional cardiologists seeking to quickly optimize and confirm revascularization decisions by providing real-time FFRangio values and advanced insights without the need for pressure wires or vasoactive drugs.

View FFRangio System →

Choose Acumen Hypotension Prediction Index (HPI) Feature Software if…

Choose the Acumen Hypotension Prediction Index (HPI) Feature Software if your critical care or surgical teams need a proactive monitoring tool to anticipate and prevent hypotensive events. This system is best suited for clinicians who require early warnings (up to 15 minutes prior) and actionable insights into hemodynamic instability, enabling timely interventions to improve patient outcomes in high-acuity settings.

View Acumen Hypotension Prediction Index (HPI) Feature Software →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FFRangio System	Acumen Hypotension Prediction Index (HPI) Feature Software
Pricing	Contact vendor for pricing information.	Unknown
Deployment	SaaS, on-prem, hybrid	Unknown
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FFRangio System

The FFRangio System's 'wire-free and drug-free' approach fundamentally simplifies the FFR procedure, directly enhancing usability and workflow in the cath lab. Its intuitive user interface and seamless integration further contribute to a streamlined user experience.

Clinical Value

Acumen Hypotension Prediction Index (HPI) Feature Software

While both offer significant clinical value, the Acumen HPI software explicitly states a 'Demonstrated reduction in incidence, duration, and severity of intraoperative hypotension,' indicating a direct, measurable improvement in patient outcomes and safety. Tool A offers advanced diagnostic insights, but Tool B's claim is a stronger, quantifiable outcome.

Pricing & Value

Tie

Both tools require direct contact with the vendor for pricing information, making it impossible to compare their cost-effectiveness or overall value without specific details. Neither provides publicly available pricing or detailed value propositions beyond their core functionalities.

Enterprise Readiness

Acumen Hypotension Prediction Index (HPI) Feature Software

Tool B explicitly confirms HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical for enterprise adoption in healthcare. While Tool A has ISO 27001 certification for information security, its HIPAA and BAA status are not explicitly stated as confirmed.

Innovation

Tie

Both tools represent significant innovations in their respective fields. Tool A introduces a fundamentally less invasive and faster method for FFR using AI, while Tool B offers a 'first-of-its-kind' predictive capability for hypotension, leveraging machine learning to address critical clinical needs.

Support & Docs

Acumen Hypotension Prediction Index (HPI) Feature Software

Edwards Lifesciences (Tool B) is a significantly larger and more established medical device company with a broader product portfolio, which typically translates to more extensive and formalized support infrastructure, training programs, and readily available documentation for clinicians and technical staff. While specific details for Acumen HPI aren't public, the company's overall reputation and resources suggest superior support compared to a smaller, more specialized company like CathWorks.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FFRangio System	Acumen Hypotension Prediction Index (HPI) Feature Software
Name	FFRangio System	Acumen Hypotension Prediction Index (HPI) Feature Software
Company	CathWorks	Edwards Lifesciences
Primary Function	Delivers wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease.	Predictive monitoring tool that uses machine learning to detect and alert clinicians to the likelihood of a hypotensive event before it occurs, aiding in proactive hemodynamic management and improving patient outcomes.
Key Technology	Artificial intelligence aids in quick angiogram analysis.	Machine learning algorithms for predictive analysis of blood pressure waveforms.
Core Measurement/Prediction	Real-time FFRangio values at every point on the coronary tree; Simulated pullback curve differentiates functional patterns of CAD; Lesion Impact feature to assess residual ischemia; Integrated sizing tool for non-invasive lesion measurements.	Hypotension Prediction Index (HPI) parameter (0-100 score); Predicts hypotension up to 15 minutes before an event.
Key Benefit/Impact	Eliminates the need for invasive pressure wires, drugs, or a guide catheter.	Demonstrated reduction in incidence, duration, and severity of intraoperative hypotension.

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and Acumen Hypotension Prediction Index (HPI) Feature Software.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of the FFRangio System versus the Acumen HPI Feature Software?

The FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease, helping to determine if a coronary stent is needed. In contrast, the Acumen HPI software is a predictive monitoring tool that uses machine learning to detect and alert clinicians to the likelihood of a hypotensive event before it occurs, aiding in proactive hemodynamic management for surgical and non-surgical patients.

How do these tools leverage artificial intelligence and what data do they analyze?

The FFRangio System utilizes AI for quick angiogram analysis, using artificial intelligence and advanced computational modeling to analyze routine coronary angiograms and create a patient-specific 3D model of the coronary arteries. The Acumen HPI software employs machine learning algorithms to perform predictive analysis of blood pressure waveforms, specifically evaluating the peripheral arterial waveform to generate a Hypotension Prediction Index (HPI) score.

What are the integration requirements for each system within a clinical environment?

The FFRangio System is deployed on-premise and integrates seamlessly with existing cath lab equipment, C-arm angiography systems, and PACS. The Acumen HPI software is integrated into the Edwards Lifesciences HemoSphere advanced monitoring platform and is compatible with Acumen IQ Cuff and Sensor.

What are the key differences in patient impact or benefits offered by each tool?

The FFRangio System eliminates the need for invasive pressure wires, drugs, or a guide catheter, providing accurate multi-vessel FFR results to optimize PCI decisions and potentially reducing radiation exposure. The Acumen HPI software predicts hypotension up to 15 minutes before an event, with demonstrated reductions in the incidence, duration, and severity of intraoperative hypotension, thereby aiding proactive hemodynamic management.

Do these systems require invasive procedures or integrate with existing invasive/non-invasive monitoring?

The FFRangio System eliminates the need for invasive pressure wires, drugs, or a guide catheter, relying on routine angiograms for its analysis. The Acumen HPI software is compatible with both invasive monitoring via an arterial line (Acumen IQ sensor) and non-invasive monitoring using the Acumen IQ cuff.